Psomagen Past Earnings Performance
Past criteria checks 0/6
Psomagen's earnings have been declining at an average annual rate of -1041.2%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 20.1% per year.
Key information
-1,041.2%
Earnings growth rate
-1,036.5%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -20.1% |
| Return on equity | -19.5% |
| Net Margin | -18.1% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses Breakdown
How Psomagen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 33,315 | -6,017 | 9,880 | 1,353 |
| 31 Dec 23 | 32,275 | -4,288 | 8,586 | 1,353 |
| 30 Sep 23 | 35,219 | -2,370 | 8,000 | 1,943 |
| 30 Jun 23 | 39,988 | 0 | 8,227 | 1,943 |
| 31 Dec 22 | 43,374 | -1,048 | 10,553 | 1,943 |
Quality Earnings: A950200 is currently unprofitable.
Growing Profit Margin: A950200 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A950200's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A950200's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A950200 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (52.8%).
Return on Equity
High ROE: A950200 has a negative Return on Equity (-19.55%), as it is currently unprofitable.